Entering text into the input field will update the search result below

OPKO Health, Inc. (OPK) CEO Dr. Phillip Frost on Q1 2020 Results - Earnings Call Transcript

May 06, 2020 10:52 PM ETOPKO Health, Inc. (OPK)2 Comments
SA Transcripts profile picture
SA Transcripts

Call end: 17:12

OPKO Health, Inc. (NASDAQ:OPK)

Q1 2020 Earnings Conference Call

May 6, 2020 4:30 PM ET

Company Participants

Yvonne Briggs - LHA IR

Phillip Frost - Chairman and CEO

Steve Rubin - EVP

Jon Cohen - SVP, OPKO Health and Executive Chairman, BioReference Laboratories

Adam Logal - Chief Financial Officer

Charles Bishop - Chief Executive Officer, OPKO Renal Division

Conference Call Participants

Maury Raycroft - Jefferies

I-Eh Jen - Laidlaw & Company

Ted Tenthoff - Piper Sandler


Ladies and gentlemen, thank you for standing by. And welcome to the OPKO Business Update and First Quarter Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Thank you. I’ll now turn the conference over to

I would now like to turn the conference over to Yvonne Briggs. You may begin.

Yvonne Briggs

Thank you, operator. Good afternoon. This is Yvonne Briggs with LHA. Thank you all for joining today’s call to discuss OPKO Health’s financial results for the first quarter of 2020.

I’d like to remind you that any statements made during this call by management other than statements of historical facts will be considered forward-looking and as such will be subject to risks and uncertainties that could materially affect the Company’s expected results. Those forward-looking statements include without limitation, the various risks described in the Company’s SEC filings including the Annual Report on Form 10-K for the year ended December 31, 2019 and in subsequently filed SEC reports. Importantly, this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, May 6, 2020. Except as required by law, OPKO undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this call.

Recommended For You

Comments (2)

Opko looks like they will be in a “sweet spot” very soon. Covid-19 testing is still increasing, antibody testing is just getting started and as doctors start seeing patients again Rayaldee prescriptions and 4-K Score tests will resume their upward paths.
Everything sounds reasonable . Will see
To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.